Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

NCT01275196 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Nilotinib
DRUG: Imatinib

Sponsor

Novartis Pharmaceuticals